Cancer Research

The appointment of industry veterans from Bristol Myers Squibb and Iovance Biotherapeutics highlights a major transition toward clinical-stage operations for cell therapy developers. This leadership influx comes at a pivotal moment for Link Cell Therapies as it progresses into the Phase I clinical

A multi-layered screening strategy combining mammography and ultrasound offers the highest probability of catching treatable cancers at their most localized and manageable stage. As the landscape of preventive medicine continues to evolve in 2026, healthcare professionals are increasingly

The core architecture of a chimeric antigen receptor relies on a single-chain variable fragment linked to intracellular signaling components that ignite T cell proliferation. As the pharmaceutical industry entered the second half of the current decade, the shift from experimental novelty to

Polydopamine nanotubes provide a versatile clinical tool that can disrupt cancer cell activity through both photothermal heating and localized electrical stimulation. For years, the challenge of delivering targeted therapy without damaging surrounding healthy tissue has remained a central hurdle in

Patients who previously failed treatment with lenvatinib monotherapy showed a renewed response when the drug was paired with the novel experimental agent E7386. This breakthrough in gynecologic oncology represents a turning point for patients facing advanced endometrial cancer after exhausting

Modern drug discovery is shifting away from labor-intensive physical screening toward a hierarchical computational approach that merges machine learning with structural biology. This methodological evolution represents a major paradigm shift in oncology, where researchers at the Hangzhou Lin’an